HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users
Abstract Background Statins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the pharmacological target o...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2026-04-01
|
| Ráidu: | Human Genomics |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s40246-026-00962-7 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|